Core Insights - Zhengye Biology (ZYBT) experienced a 2.33% increase in stock price, reaching $7.777 per share with a total market capitalization of $369 million as of August 20 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is expected to be 11.311 million RMB, showing a significant decline of 64.04% year-on-year [1] Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]
正业生物上涨2.33%，报7.777美元/股，总市值3.69亿美元